Equities

Cardio Diagnostics Holdings Inc

CDIO:NAQ

Cardio Diagnostics Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.28
  • Today's Change0.000 / 0.07%
  • Shares traded312.65k
  • 1 Year change-26.51%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.

  • Revenue in USD (TTM)39.14k
  • Net income in USD-8.77m
  • Incorporated2021
  • Employees7.00
  • Location
    Cardio Diagnostics Holdings Inc311 W. Superior Street, Suite 444CHICAGO 60645United StatesUSA
  • Phone+1 (302) 281-2147
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CERo Therapeutics Holdings Inc0.00-2.54m6.11m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Xenetic Biosciences Inc2.52m-4.70m6.12m4.00--0.8219--2.43-3.05-3.051.644.830.2314----630,087.50-43.12-48.91-48.61-52.82-----186.33-682.42----0.00--48.80--36.90------
Alzamend Neuro Inc0.00-7.39m6.57m4.00---------10.69-10.690.00-1.410.00----0.00-344.10-177.86---257.81-----------363.62--------33.14------
Cardio Diagnostics Holdings Inc39.14k-8.77m6.70m7.00--2.12--171.28-0.4899-0.48990.00210.13190.0073--9.135,591.43-163.16---268.73-------22,414.13-----9.320.0295--1,696.84---79.72------
Adial Pharmaceuticals Inc0.00-12.19m6.72m4.00--1.05-----5.26-5.300.000.99610.00----0.00-279.27-182.35-320.96-235.45-----------14.250.00------35.14------
Moleculin Biotech Inc0.00-25.17m6.74m18.00--0.3428-----11.62-11.620.006.910.00----0.00-69.24-46.84-83.35-51.49------------0.00-------2.56---21.54--
Eterna Therapeutics Inc162.00k-23.94m6.93m8.00------42.75-4.42-4.420.0299-1.580.0035--0.267320,250.00-51.20-169.05-62.39-223.00-111.11---14,765.43-682.61---10.1210.22-----68.8911.84---58.86--
Enzolytics Inc0.00-119.19k6.96m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
CeCors Inc-100.00bn-100.00bn6.97m6.00---------------0.0163------------------------------------22.70------
NLS Pharmaceutics AG0.00-12.17m7.08m3.00---------0.3188-0.31880.00-0.27240.00----0.00-218.86-272.62---------------81.34--------26.21------
Viaderma Inc17.80m2.31m7.09m75.000.00030.000021.310.398516.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Traws Pharma Inc226.00k-137.05m7.19m16.00------31.83-5.53-5.530.01020.2410.0092--12.9114,125.00-557.63-63.43-896.39-85.72-----60,641.15-3,257.92----0.00--0.00-28.720.0844------
Mosaic Immunoengineering Inc0.00-1.21m7.24m3.00---------0.1674-0.16740.00-0.89040.00----0.00-634.64-----------------14.05--------57.65------
BioNexus Gene Lab Corp9.18m-2.21m7.26m30.00--0.7474--0.7901-0.1108-0.11080.58070.54030.96477.195.77---23.17-3.83-27.98-5.0213.8814.55-24.02-3.044.87-118.920.00---10.60115.07-638.56--30.40--
NuCana PLC (ADR)0.00-37.54m7.29m25.00--1.44-----234.80-234.800.002.230.00----0.00-91.91-41.01-177.64-48.07------------0.0689------13.71---21.70--
Data as of Sep 20 2024. Currency figures normalised to Cardio Diagnostics Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

7.43%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20241.07m4.46%
The Vanguard Group, Inc.as of 30 Jun 2024232.14k0.97%
Geode Capital Management LLCas of 30 Jun 2024174.55k0.73%
UBS Securities LLCas of 30 Jun 202490.91k0.38%
Two Sigma Securities LLCas of 30 Jun 202457.43k0.24%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202448.62k0.20%
SSgA Funds Management, Inc.as of 30 Jun 202443.50k0.18%
PNC Bank, NA (Investment Management)as of 30 Jun 202440.50k0.17%
LPL Financial LLCas of 30 Jun 202415.20k0.06%
Caldwell Sutter Capital, Inc. (Investment Management)as of 30 Jun 20248.10k0.03%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.